MAPK9 and breast cancer: Conversely, treatment of breast cancer cell lines and a mouse xenograft model with docetaxel, a potential breast cancer drug, causes cell death in hypoxic conditions through c-Jun N-terminal Kinase 2 (JNK2)-PHD1 mediated HIF-1α degradation [175].